BofA warns Fed risks policy mistake with early rate cuts
Magnetar Financial LLC, a ten percent owner of CoreWeave, Inc. (CRWV), sold 915,767 shares of Class A Common Stock on August 15, 2025. The shares were sold at a price of $100.15, resulting in a total transaction value of $91,675,507. The sale comes as CoreWeave, currently valued at $48.8 billion, has seen its stock decline by 21% in the past week, according to InvestingPro data.
The sales were executed across multiple entities associated with Magnetar, including Magnetar Capital Master Fund, Ltd, Magnetar Constellation Master Fund, Ltd, Magnetar Longhorn Fund LP, Magnetar SC Fund Ltd, Magnetar Xing He Master Fund Ltd, Purpose Alternative Credit Fund - F LLC, Purpose Alternative Credit Fund - T LLC, Longhorn Special Opportunities Fund LP, CW Opportunity (SO:FTCE11B) LLC and CW Opportunity 2 LP, the general partner of Magnetar Structured Credit Fund, LP and the manager of Magnetar Alpha Star Fund LLC and Magnetar Lake Credit Fund LLC. InvestingPro analysis shows the company is rapidly burning through cash with a negative free cash flow yield, while trading at high valuation multiples across various metrics.
Following these transactions, Magnetar Financial LLC continues to hold a significant number of CoreWeave, Inc. shares indirectly through various funds and entities. For comprehensive insider trading analysis and 17 additional key ProTips about CoreWeave, visit InvestingPro.
In other recent news, Core Scientific Inc. experienced a revenue shortfall due to its strategic wind-down of Bitcoin mining operations, though its high-performance computing business contributed to an earnings beat. Macquarie has reiterated a Neutral rating with a $15 price target for Core Scientific. Meanwhile, CoreWeave has seen a flurry of activity, with MoffettNathanson raising its price target from $56 to $65, maintaining a Neutral rating, based on revised forecasts and an increased enterprise value to operating income multiple for 2029. Additionally, major banks like JPMorgan, Goldman Sachs, and Morgan Stanley (NYSE:MS) have conducted block trades of CoreWeave shares, selling millions of shares in the mid-$90s range. HSBC has expressed concerns about CoreWeave’s future margin performance, reiterating a Reduce rating with a $32 price target, citing a significant gap in non-GAAP EPS estimates compared to consensus expectations. BofA Securities has also adjusted its outlook on CoreWeave, lowering its price target to $168 from $185 while maintaining a Neutral rating, following the company’s quarterly results that showed a solid performance but with slightly lower-than-expected revenue beat and guidance raise. These developments highlight the ongoing evaluations and strategic decisions impacting both Core Scientific and CoreWeave.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.